# Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)

> **NCT00168922** · PHASE2 · UNKNOWN · sponsor: **Charite University, Berlin, Germany** · enrollment: 50 (—)

## Conditions studied

- Recurrent Small Cell Lung Cancer

## Interventions

- **DRUG:** Bendamustin/Ribomustin

## Key facts

- **NCT ID:** NCT00168922
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2001-02
- **Primary completion:** —
- **Final completion:** 2006-12
- **Target enrollment:** 50 (—)
- **Last updated:** 2006-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00168922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00168922, "Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00168922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*